Disc Medicine’s (IRON) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Disc Medicine (NASDAQ:IRON) in a research report report published on Monday morning, Benzinga reports. The firm currently has a $70.00 target price on the stock.

IRON has been the topic of several other reports. Scotiabank started coverage on Disc Medicine in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $62.00 price target on the stock. Jefferies Financial Group initiated coverage on Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target on the stock. Wells Fargo & Company initiated coverage on Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Wedbush reissued an “outperform” rating and set a $57.00 price objective on shares of Disc Medicine in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $66.40.

Disc Medicine Price Performance

Shares of NASDAQ:IRON opened at $44.82 on Monday. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The firm has a market capitalization of $1.33 billion, a PE ratio of -12.21 and a beta of 0.59. The business has a 50-day moving average of $48.63 and a two-hundred day moving average of $42.44.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. As a group, research analysts anticipate that Disc Medicine will post -4.19 earnings per share for the current year.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors have recently made changes to their positions in IRON. Amalgamated Bank increased its stake in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after acquiring an additional 337 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Disc Medicine in the 2nd quarter worth approximately $129,000. SG Americas Securities LLC boosted its holdings in shares of Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock worth $183,000 after acquiring an additional 1,247 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Disc Medicine in the 1st quarter worth approximately $211,000. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.